合成了两种单羰基二甲氨基姜黄素，一种来自丙酮（C3），另一种来自环己烷（C6），旨在研究它们的光物理性质和抗癌光动力潜力。化合物C6表现出比C3更低的吸光度和荧光。光漂白研究表明，DMSO 中的 C3 和 C6 光稳定性行为显着不同。 C3 完全光转化为吸收波长低于母体化合物的新物种，而 C6 在 15 mW/cm2 的 λ = 440 nm 照射 30 分钟后达到光稳定相，其中少量初始化合物与一些光产品具有较高和较低的吸光度。这两种化合物在水性环境中照射后都能产生大量的 ROS，并在皮肤癌细胞（A431 细胞）中表现出成功的细胞内定位。经过暗细胞毒性研究后，分别选择 C3 和 C6 的 5 μM 和 1 μM 浓度进行 PDT 评估。 C3 对 A431 细胞呈现光剂量依赖性光动力活性，光照射（440 nm，15 mW/cm2）12 分钟后细胞活力为 40%。另一方面，C6 显示出双相光剂量 PDT 效应，在光照 5 分钟后细胞活力逐渐下降至 50%，然后在光照 8 和 12 分钟后再次增加。 C6 的光动力学性能可能为开发具有降低的长时间光敏性的 PS 提供新的见解。版权所有 © 2024 Elsevier B.V. 保留所有权利。

Two monocarbonyl dimethylamino curcuminoids, one derived from acetone (C3) and the second one from cyclohexane (C6), were synthesized aiming to study their photophysical properties and anticancer photodynamic potential. Compound C6 exhibited lower absorbance and fluorescence than C3. Photobleaching studies showed that C3 and C6 photostability behavior in DMSO differ significantly. C3 was completely photoconverted into a new species absorbing at lower wavelength than the parent compound, whereas, C6, upon a 30 min irradiation at λ = 440 nm with 15 mW/cm2 reached a photostationary phase where a smaller amount of the initial compound coexists with some photoproducts of higher and lower absorbance. Both compounds were able to generate significant amounts of ROS upon irradiation in an aqueous environment and exhibited successful intracellular localization in skin cancer cells (A431 cells). After dark cytotoxicity studies the concentrations of 5 μM and 1 μM for C3 and C6, respectively, were selected for the PDT assessment. C3 presented light dose-dependent photodynamic activity against A431 cells, resulting in 40 % cell viability after 12 min of light irradiation (440 nm, 15 mW/cm2). On the other side, C6 showed a biphasic light dose PDT effect with cell viability gradually decreasing up to 50 % after 5 min of light exposure, and then increasing again after 8 and 12 min of light exposure. The photodynamic performance of C6 may provide a new insight into the development of PSs with reduced prolonged photosensitivity.Copyright © 2024 Elsevier B.V. All rights reserved.